Compare CHCT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | RCEL |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.5M | 403.3M |
| IPO Year | 2015 | 2018 |
| Metric | CHCT | RCEL |
|---|---|---|
| Price | $14.66 | $15.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $17.00 | ★ $20.10 |
| AVG Volume (30 Days) | 345.0K | ★ 540.5K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 8.97% | N/A |
| EPS Growth | ★ 134.78 | 27.20 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $121,195,000.00 | $71,610,000.00 |
| Revenue This Year | $4.65 | $33.44 |
| Revenue Next Year | $4.57 | $21.95 |
| P/E Ratio | $66.82 | ★ N/A |
| Revenue Growth | 4.67 | ★ 11.45 |
| 52 Week Low | $12.58 | $3.22 |
| 52 Week High | $19.17 | $18.43 |
| Indicator | CHCT | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 54.17 |
| Support Level | $14.39 | $14.67 |
| Resistance Level | $17.96 | $16.90 |
| Average True Range (ATR) | 0.40 | 1.23 |
| MACD | 0.20 | -0.13 |
| Stochastic Oscillator | 76.40 | 28.72 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.